|
November 7, 2022
 |
| Florida Medical Boards Ban Gender Transition Procedures for Minors |
| by Joshua Arnold |
| The Florida Board of Medicine and Board of Osteopathic Medicine on Friday adopted standards of care regarding the treatment of individuals suffering from gender dysphoria. During a joint board meeting, the boards each voted to adopt new Practice Standards for the Treatment of Gender Dysphoria that prevent doctors from performing experimental gender transition procedures on minors, including puberty blockers, cross-sex hormones, and gender transition surgeries. |
|
|
|
 |
| Dems Become the Election Deniers They Scoffed |
| by Suzanne Bowdey |
| A year into his dumpster fire of a presidency, Joe Biden's team must have already assumed the midterms were lost. By January, when the president had collected more failures than most presidents do in two terms, a tiny seed was being planted. Asked if America would have "free and fair" elections in 2022, Biden replied, "Oh, yeah, I think it easily could be illegitimate. ... I'm not going to say it's going to be legit." Not a single ballot had been cast, and the president was already declaring the whole thing rigged. |
|
|
|
 |
| Woke Censorship Doesn't Fly at Penguin Random House |
| by Joshua Arnold |
| Penguin Random House rejected a demand to cancel a book deal with Supreme Court Justice Amy Coney Barrett. Over 700 employees in the publishing world have signed an open letter urging the publishing giant to cancel the book deal, first reported in 2021, for her decision this summer to overturn Roe v. Wade. But, in another sign that the woke mob is losing its leverage, Penguin Random House refused to cave. |
|
|
|
 |
| Pharmaceutical Company Proves Pro-Life Laws Won't Hurt Your State |
| by Renata Kiss |
| This past summer, when Indiana Governor Eric Holcomb (R) signed legislation outlawing abortion almost completely in the state, Eli Lilly and Company, a major pharmaceutical company, stated that "given this new law, we will be forced to plan for more employment growth outside our home state," and that the law "will hinder Lilly's - and Indiana's - ability to attract diverse scientific, engineering and business talent from around the world." But after a series of mixed messaging that tried to target the overturning of Roe v. Wade, CEO David Ricks quickly changed his mind. |
|
|
|
|
|
